Navigation Links
Genetic aberration paves the way for new treatment of cancer disease
Date:11/6/2013

12-15 years of development and millions of dollars are typically the costs, when companies develop a new anti-cancer drug. Therefore all short cuts to a treatment are welcome. Researchers at Department of Veterinary Disease Biology, University of Copenhagen, recently discovered such a potential short cut.

"Our new research shows, that we might be able to introduce a treatment faster and cheaper than usual in the development of cancer treatment, and we estimate that it will be efficient in around 10 per cent of patients with colorectal cancer," says MD and PhD student Sune Nygrd, Department of Veterinary Disease Biology, University of Copenhagen.

Re-use of existing breast cancer treatment

In the new study the researchers have shown that around 10 per cent of colorectal cancer patients harbor an aberration in the gene called TOP2A in their cancer cells. These tumors could potentially benefit from treatment with a specific chemotherapeutic drug a so-called "anti-TOP2A treatment", which is already used in breast cancer patients with this gene aberration.

Clinical study begins

Approximately 600,000 patients die of colorectal cancer each year worldwide.

"If the first treatment doesn't cure a patient with colorectal cancer, the possibilities of additional treatment are limited," says Nils Brnner, MD, professor at University of Copenhagen.

"Therefore it is very important to find a new, efficient treatment," he adds.

The research group from the Department of Veterinary Disease Biology and professor Per Pfeiffer at Odense University Hospital have received funds from The Danish Cancer Society to initiate a clinical trial. Here it will be tested, if patients with the TOP2A gene defect could benefit from the targeted anti-TOP2A treatment.

"It is unique to go from a discovery in the laboratory towards a treatment for cancer patients at this pace. This is only possible when researchers and doctors work closely together," says Nils Brnner, University of Copenhagen.


'/>"/>

Contact: Nils Brünner
nbr@sund.ku.dk
45-26-14-47-08
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Genetic study proves Israels wild boars originated in Europe
2. Dolphin genetic study provides revelations
3. Genetic rarity rules in wild guppy population, study finds
4. GenSeq: Updated nomenclature for genetic sequences to solve taxonomic determination issues
5. BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
6. HIV -- Geneticists map human resistance to AIDS
7. Measuring segments of genetic material may help predict and monitor recurrence after thyroid cancer
8. Genetic variants associated with bronchodilator responsiveness
9. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
10. New software traces origins of genetic disorders 20 times more accurately
11. 2 genetic wrongs make a biochemical right
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
Breaking Biology Technology: